Physician profile
Robert S Byrum
NPI 1487620654
$17,800.15
in general payments reported to CMS, 2019-2025
32 companies · $8,557 in 2025
The $8,557 reported for 2025 was more than what 92% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $808 · 2020: $2,332 · 2021: $531 · 2022: $4,715 · 2023: $563 · 2024: $294 · 2025: $8,557.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $8,000 · Food and Beverage: $1,414.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $8,000.00 |
| Food and Beverage | $1,413.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $12,961.63 | 2021-2025 | Da Vinci Surgical System |
| Ethicon INC. | $1,353.95 | 2020 | |
| Covidien Lp | $850.00 | 2020 | |
| Glaxosmithkline, LLC. | $498.31 | 2019-2025 | Nucala, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals Lp | $373.47 | 2019-2025 | Breztri, Airsupra, Tezspire |
| Actelion Pharmaceuticals US, INC. | $181.85 | 2019-2025 | Uptravi, Opsumit |
| Merck Sharp & Dohme LLC | $143.29 | 2019-2025 | Winrevair, Zerbaxa, Recarbrio |
| Galvanize Therapeutics, INC | $130.43 | 2025 | Aliya System |
| Auris Health, INC. | $128.46 | 2019 | |
| Inogen, INC. | $127.14 | 2022-2025 | Inogen |
| Novartis Pharmaceuticals Corporation | $122.81 | 2019-2024 | |
| United Therapeutics Corporation | $117.31 | 2021-2025 | Tyvaso, Tyvaso |
| Grifols USA, LLC | $107.39 | 2019-2025 | Prolastin-C Liquid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $103.76 | 2020-2025 | Ofev |
| Genzyme Corporation | $82.13 | 2019-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $78.63 | 2019-2024 | Arikayce |
| Amgen INC. | $59.84 | 2022-2024 | Tezspire, Lumakras |
| Mylan Specialty L.P. | $41.13 | 2019-2024 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $36.96 | 2023 | Dupixent |
| Sunovion Pharmaceuticals INC. | $35.36 | 2019 | |
| Viatris Specialty LLC | $34.66 | 2025 | Yupelri |
| Pfizer INC. | $32.39 | 2024 | |
| Abbvie INC. | $29.90 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $28.14 | 2022 | |
| Verona Pharma, INC. | $22.75 | 2025 | Ohtuvayre |
| Takeda Pharmaceuticals U.S.A., INC. | $21.38 | 2024 | Glassia |
| Gilead Sciences, INC. | $20.09 | 2021 | |
| Ani Pharmaceuticals, INC. | $18.44 | 2025 | Purified Cortrophin Gel |
| Shionogi INC | $17.45 | 2023 | Fetroja |
| Avanos Medical | $17.24 | 2022 | |
| Allergan, INC. | $12.18 | 2019 | |
| Quidel Corporation | $11.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Byrum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.